The race to develop the next generation of checkpoint inhibitors that could rival Keytruda has become one of the most watched in oncology. Who wouldn’t want a slice of the drug’s gushing multibillion-dollar revenue stream?

The FDA has found new clusters of specific types of cancer linked to the scar tissue that forms around breast implants, as part of its ongoing, yearslong review of the risks that can come with the procedure.

Allakos has achieved an undesired hat trick. Across three phase 3 trials, the biotech has now significantly reduced levels of a troublesome white blood cell without improving symptoms, driving it to rethink the development of an anti-Siglec-8 antibody that was once among the hottest prospects in biotech.

Jumping into the health and wellness sector once seemed like an easy win for some pharma companies, but the tough times are increasingly extending beyond biotech. That certainly seems to be the case for InMed Pharmaceuticals, which is backing out of the wellness arena less than a year after the Canadian drug developer acquired cannabinoid company BayMedica.

Another crop of health-focused additions to Apple’s eponymous wearable device is ready for harvest. The tech giant unveiled the new features during a keynote presentation Wednesday, with the rollout slated to begin later this month.

Silence Therapeutics’ efforts to push SLN124 as a potential treatment for myelodysplastic syndrome (MDS) may have hit a roadblock earlier this year, but the FDA appears to have faith in the therapy’s abilities for another type of blood cancer.

The legal troubles continue for Philips and the seemingly never-ending recall of around 5.5 million of its breathing support machines.

Mirati Therapeutics has taken the lid off updated data on KRAS inhibitor adagrasib in colorectal cancer. Having established itself as the front-runner in the space last year, the biotech has presented a new look at the phase 1/2 data that largely reaffirm the earlier findings.

Brickell Biotech is shedding its old name to pursue Fresh Tracks, rebranding to represent its potential evolution into a clinical-stage pharmaceutical company.

What do VC firm Arch Venture Partners, Moderna’s former head of infectious disease vaccines Giuseppe Ciaramella, Ph.D., and Alnylam founding CEO John Maraganore, Ph.D., have in common? They’re all stakeholders in a new biotech launching in the hopes of scaling the heights of the RNA-based therapy market.